Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8151 to 8200 of 8901 results

  1. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

  2. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79

  3. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1120.

  4. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

  5. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

  6. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

  7. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

  8. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

  9. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

  10. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

  11. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

  12. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

  13. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

  14. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

  15. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

  16. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

  17. Laparoscopic surgery for hernia (TA18)

    This guidance has been replaced by NICE technology appraisal guidance 83.

  18. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

  19. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

  20. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

  21. Lubiprostone for treating chronic idiopathic constipation (TA318)

    This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).